MA41827A - Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton - Google Patents
Formes solvatées d'un inhibiteur de la tyrosine kinase de brutonInfo
- Publication number
- MA41827A MA41827A MA041827A MA41827A MA41827A MA 41827 A MA41827 A MA 41827A MA 041827 A MA041827 A MA 041827A MA 41827 A MA41827 A MA 41827A MA 41827 A MA41827 A MA 41827A
- Authority
- MA
- Morocco
- Prior art keywords
- tyrosine kinase
- kinase inhibitor
- solvated forms
- bruton tyrosine
- bruton
- Prior art date
Links
- 229940124291 BTK inhibitor Drugs 0.000 title 1
- 229940125814 BTK kinase inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
- G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
- G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562139594P | 2015-03-27 | 2015-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41827A true MA41827A (fr) | 2018-01-30 |
Family
ID=57006292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041827A MA41827A (fr) | 2015-03-27 | 2016-03-24 | Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20180072738A1 (enExample) |
| EP (1) | EP3273961A4 (enExample) |
| JP (2) | JP2018509457A (enExample) |
| CN (1) | CN107530346A (enExample) |
| AU (1) | AU2016243116A1 (enExample) |
| BR (1) | BR112017020744A2 (enExample) |
| CA (1) | CA2981048A1 (enExample) |
| HK (2) | HK1248147A1 (enExample) |
| MA (1) | MA41827A (enExample) |
| MX (1) | MX2017012430A (enExample) |
| WO (1) | WO2016160598A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA37711A1 (fr) | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of proton tyrosine kinase inhibitor |
| EP3337485B1 (en) * | 2015-08-19 | 2021-03-17 | Sun Pharmaceutical Industries Ltd | Crystalline forms of ibrutinib |
| CZ2016276A3 (cs) * | 2016-05-11 | 2017-11-22 | Zentiva, K.S. | Pevné formy volné báze ibrutinibu |
| US10183024B2 (en) | 2016-12-02 | 2019-01-22 | Apotex Inc. | Crystalline forms of ibrutinib |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| EP3575300A1 (en) | 2018-05-31 | 2019-12-04 | Apotex Inc. | Novel crystalline forms of ibrutinib |
| US10688050B1 (en) | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| EP3669867A1 (en) | 2018-12-21 | 2020-06-24 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| CA3154566A1 (en) * | 2019-09-18 | 2021-03-25 | Prelude Therapeutics Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| CN114478547B (zh) * | 2020-10-23 | 2026-01-23 | 上海润石医药科技有限公司 | 固体形式的布鲁顿酪氨酸激酶抑制剂化合物及其用途 |
| WO2023242384A1 (en) | 2022-06-17 | 2023-12-21 | Krka, D.D., Novo Mesto | Crystalline form of ibrutinib |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| DE3303707A1 (de) * | 1983-02-04 | 1984-08-09 | Dynamit Nobel Ag, 5210 Troisdorf | Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| ES2111065T5 (es) | 1991-04-16 | 2005-06-16 | Nippon Shinyaku Company, Limited | Procedimiento para producir una dispersion solida. |
| CZ282760B6 (cs) | 1991-11-22 | 1997-09-17 | Procter And Gamble Pharmaceuticals, Inc. | Risedronátové prostředky se zpožděným uvolňováním |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| WO1994008568A1 (fr) | 1992-10-16 | 1994-04-28 | Nippon Shinyaku Co., Ltd. | Procede pour fabriquer des matrices de cire |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| KR19990014865A (ko) | 1995-05-17 | 1999-02-25 | 피터 이. 브래이브맨 | 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들 |
| CO5210907A1 (es) * | 1999-05-12 | 2002-10-30 | Novartis Ag | Solvatos de pometrozina, insecticidamente activos, composiciones que contienen estos compuestos y metodos tanto para producir dichos compuestos y composiciones como para controlar plagas animales con estas composiciones |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| GB0108903D0 (en) * | 2000-10-05 | 2001-05-30 | Aventis Pharm Prod Inc | Novel crystalline forms of a factor Xa inhibitor |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| US7711492B2 (en) | 2003-09-03 | 2010-05-04 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for diagnosing lymphoma types |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| EP2139487B1 (en) * | 2007-03-28 | 2015-11-11 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| US8541391B2 (en) * | 2010-10-28 | 2013-09-24 | Viropharma Incorporated | Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole |
| US8501484B2 (en) * | 2011-03-14 | 2013-08-06 | Los Alamos National Security, Llc | Preparation of cerium halide solvate complexes |
| MA37711A1 (fr) * | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| US20160287592A1 (en) | 2013-04-08 | 2016-10-06 | Pharmacyclics Llc | Ibrutinib combination therapy |
| CN105949197A (zh) * | 2014-01-29 | 2016-09-21 | 苏州晶云药物科技有限公司 | 依鲁替尼的新晶型及其制备方法 |
-
2016
- 2016-03-24 MA MA041827A patent/MA41827A/fr unknown
- 2016-03-25 WO PCT/US2016/024305 patent/WO2016160598A1/en not_active Ceased
- 2016-03-25 JP JP2017550541A patent/JP2018509457A/ja active Pending
- 2016-03-25 HK HK18107889.9A patent/HK1248147A1/zh unknown
- 2016-03-25 AU AU2016243116A patent/AU2016243116A1/en not_active Abandoned
- 2016-03-25 CA CA2981048A patent/CA2981048A1/en not_active Abandoned
- 2016-03-25 CN CN201680026436.5A patent/CN107530346A/zh active Pending
- 2016-03-25 HK HK18109251.5A patent/HK1249737A1/zh unknown
- 2016-03-25 MX MX2017012430A patent/MX2017012430A/es unknown
- 2016-03-25 EP EP16773859.0A patent/EP3273961A4/en not_active Withdrawn
- 2016-03-25 BR BR112017020744A patent/BR112017020744A2/pt not_active Application Discontinuation
- 2016-03-25 US US15/561,615 patent/US20180072738A1/en not_active Abandoned
-
2018
- 2018-12-18 US US16/224,565 patent/US20190367519A1/en not_active Abandoned
-
2019
- 2019-11-27 US US16/697,865 patent/US20200347063A1/en not_active Abandoned
-
2021
- 2021-05-12 US US17/318,148 patent/US20220106317A1/en not_active Abandoned
- 2021-11-17 JP JP2021187233A patent/JP2022033783A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20180072738A1 (en) | 2018-03-15 |
| JP2022033783A (ja) | 2022-03-02 |
| HK1248147A1 (zh) | 2018-10-12 |
| CN107530346A (zh) | 2018-01-02 |
| CA2981048A1 (en) | 2016-10-06 |
| BR112017020744A2 (pt) | 2018-07-17 |
| MX2017012430A (es) | 2018-07-06 |
| AU2016243116A1 (en) | 2017-10-19 |
| JP2018509457A (ja) | 2018-04-05 |
| US20200347063A1 (en) | 2020-11-05 |
| US20220106317A1 (en) | 2022-04-07 |
| WO2016160598A1 (en) | 2016-10-06 |
| EP3273961A1 (en) | 2018-01-31 |
| EP3273961A4 (en) | 2018-10-31 |
| HK1249737A1 (zh) | 2018-11-09 |
| US20190367519A1 (en) | 2019-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41350A (fr) | Synthèse d'un inhibiteur de la tyrosine kinase de bruton | |
| MA41828A (fr) | Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton | |
| MA42623A (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
| EP3414234A4 (en) | BRUTON TYROSINE KINASE HEMMER | |
| BR112017018931A2 (en) | pharmaceutical formulations of a bruton tyrosine kinase inhibitor | |
| MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
| ZA201805439B (en) | Bruton's tyrosine kinase inhibitors | |
| MA41252A (fr) | Formes solides d'un inhibiteur d'ask 1 | |
| IL250085A0 (en) | New compounds of proton tyrosine kinase inhibitor | |
| DK3303334T3 (da) | Tyrosinkinasehæmmere | |
| MA43162A (fr) | Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton | |
| HUE050842T2 (hu) | Janus-kináz inhibitor | |
| EP3273961A4 (en) | Solvated forms of a bruton's tyrosine kinase inhibitor | |
| ZA201903694B (en) | Inhibitors of bruton's tyrosine kinase | |
| MA42510A (fr) | Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton | |
| HUE066253T2 (hu) | Benzoazepin analógok a bruton tirozin kináz gátlószereként | |
| MA42509A (fr) | Formes d'adipate et compositions d'inhibiteurs de biaryle de la tyrosine kinase de bruton | |
| MA44006A (fr) | Inhibiteur pde1 | |
| EP3415146A4 (en) | INHIBITOR OF INFLAMMASOMAL ACTIVATION | |
| ZA201906887B (en) | Bruton's tyrosine kinase inhibitors | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| MA52629A (fr) | Agents inhibiteurs de la tyrosine kinase de bruton | |
| EP3415524A4 (en) | INHIBITOR OF α-SYNNUCLEINE EXPRESSION | |
| EP3556758A4 (en) | CDK4 / 6-INHIBITOR | |
| DK3286317T3 (da) | Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi |